Clinical Trials Logo

Clinical Trial Summary

In this study, the investigators propose that the addition of rituximab will lower the risk of systemic and local relapses in patients with localized PBL. Patients will be treated with 6 cycles of RCHOP-14 or RCHOP-21. The administration of radiotherapy following chemotherapy is strongly recommended, based on the findings of the retrospective IELSG study, but will be at the discretion of the treating center.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01279772
Study type Observational
Source International Extranodal Lymphoma Study Group (IELSG)
Contact
Status Terminated
Phase N/A
Start date October 2011